304 related articles for article (PubMed ID: 25170121)
1. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.
Bolaños-Meade J; Logan BR; Alousi AM; Antin JH; Barowski K; Carter SL; Goldstein SC; Hexner EO; Horowitz MM; Lee SJ; Levine JE; MacMillan ML; Martin PJ; Mendizabal AM; Nakamura R; Pasquini MC; Weisdorf DJ; Westervelt P; Ho VT
Blood; 2014 Nov; 124(22):3221-7; quiz 3335. PubMed ID: 25170121
[TBL] [Abstract][Full Text] [Related]
2. The end of knight-errantry in GVHD studies.
de Lima M
Blood; 2014 Nov; 124(22):3178-9. PubMed ID: 25414433
[TBL] [Abstract][Full Text] [Related]
3. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
4. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
[TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
[TBL] [Abstract][Full Text] [Related]
6. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
7. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.
Pidala J; Hamadani M; Dawson P; Martens M; Alousi AM; Jagasia M; Efebera YA; Chhabra S; Pusic I; Holtan SG; Ferrara JLM; Levine JE; Mielcarek M; Anasetti C; Antin JH; Bolaños-Meade J; Howard A; Logan BR; Leifer ES; Pritchard TS; Horowitz MM; MacMillan ML
Blood; 2020 Jan; 135(2):97-107. PubMed ID: 31738834
[TBL] [Abstract][Full Text] [Related]
8. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
Alousi AM; Weisdorf DJ; Logan BR; Bolaños-Meade J; Carter S; Difronzo N; Pasquini M; Goldstein SC; Ho VT; Hayes-Lattin B; Wingard JR; Horowitz MM; Levine JE;
Blood; 2009 Jul; 114(3):511-7. PubMed ID: 19443659
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG).
Lai YR; Chen YH; Hu DM; Jiang M; Liu QF; Liu L; Hou J; Schwarzenberger P; Li QC; Zhang ZM; Liu KY; Huang XJ
J Hematol Oncol; 2014 Aug; 7():59. PubMed ID: 25139202
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.
Jacobson PA; Huang J; Wu J; Kim M; Logan B; Alousi A; Grimley M; Bolaños-Meade J; Ho V; Levine JE; Weisdorf D
Biol Blood Marrow Transplant; 2010 Mar; 16(3):421-9. PubMed ID: 19925875
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
[TBL] [Abstract][Full Text] [Related]
12. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial.
Beissert S; Mimouni D; Kanwar AJ; Solomons N; Kalia V; Anhalt GJ
J Invest Dermatol; 2010 Aug; 130(8):2041-8. PubMed ID: 20410913
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
[TBL] [Abstract][Full Text] [Related]
15. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus.
Mookerjee B; Altomonte V; Vogelsang G
Bone Marrow Transplant; 1999 Sep; 24(5):517-20. PubMed ID: 10482936
[TBL] [Abstract][Full Text] [Related]
16. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.
Basara N; Blau WI; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Bone Marrow Transplant; 1998 Jul; 22(1):61-5. PubMed ID: 9678797
[TBL] [Abstract][Full Text] [Related]
18. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations.
Kim YS; Moon JI; Kim SI; Park K
Transplantation; 1999 Aug; 68(4):578-81. PubMed ID: 10480420
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
Mielcarek M; Martin PJ; Leisenring W; Flowers ME; Maloney DG; Sandmaier BM; Maris MB; Storb R
Blood; 2003 Jul; 102(2):756-62. PubMed ID: 12663454
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
Sollinger HW
Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
